Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE13.9900
- TODAY'S CHANGE (%)0.2200 (1.5977%)
- Bid / Lots13.6000/ 1
- Ask / Lots14.4800/ 1
- Open / Previous Close13.8100 / 13.7700
- Day Range
- 52 Week Range
- Volume159,085
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 3113 | 14.01 |
| 09:39 ET | 100 | 13.82 |
| 09:42 ET | 720 | 13.835 |
| 09:44 ET | 466 | 13.87 |
| 09:46 ET | 100 | 13.86 |
| 09:48 ET | 200 | 13.875 |
| 09:51 ET | 394 | 13.925 |
| 09:53 ET | 500 | 13.85 |
| 09:55 ET | 5479 | 13.94 |
| 09:57 ET | 100 | 13.93 |
| 10:00 ET | 100 | 13.96 |
| 10:06 ET | 100 | 13.96 |
| 10:09 ET | 2715 | 13.965 |
| 10:11 ET | 100 | 14 |
| 10:13 ET | 433 | 14 |
| 10:15 ET | 300 | 14.005 |
| 10:18 ET | 300 | 14.025 |
| 10:20 ET | 1800 | 14.015 |
| 10:22 ET | 200 | 13.98 |
| 10:26 ET | 1856 | 13.9524 |
| 10:27 ET | 400 | 13.92 |
| 10:31 ET | 300 | 13.87 |
| 10:33 ET | 100 | 13.84 |
| 10:36 ET | 200 | 13.86 |
| 10:38 ET | 200 | 13.81 |
| 10:40 ET | 400 | 13.8 |
| 10:42 ET | 100 | 13.81 |
| 10:45 ET | 1468 | 13.83 |
| 10:47 ET | 400 | 13.8 |
| 10:49 ET | 400 | 13.82 |
| 10:51 ET | 100 | 13.82 |
| 10:56 ET | 200 | 13.81 |
| 10:58 ET | 482 | 13.83 |
| 11:02 ET | 1054 | 13.855 |
| 11:03 ET | 300 | 13.82 |
| 11:05 ET | 200 | 13.83 |
| 11:09 ET | 100 | 13.81 |
| 11:18 ET | 100 | 13.81 |
| 11:20 ET | 100 | 13.815 |
| 11:21 ET | 358 | 13.7888 |
| 11:25 ET | 300 | 13.74 |
| 11:30 ET | 157 | 13.74 |
| 11:32 ET | 600 | 13.78 |
| 11:34 ET | 150 | 13.7601 |
| 11:36 ET | 200 | 13.775 |
| 11:41 ET | 200 | 13.78 |
| 11:43 ET | 1200 | 13.81 |
| 11:45 ET | 714 | 13.82 |
| 11:48 ET | 400 | 13.83 |
| 11:57 ET | 310 | 13.85 |
| 12:01 ET | 100 | 13.835 |
| 12:06 ET | 100 | 13.835 |
| 12:08 ET | 1902 | 13.82 |
| 12:10 ET | 8345 | 13.89 |
| 12:12 ET | 200 | 13.93 |
| 12:14 ET | 446 | 13.93 |
| 12:17 ET | 300 | 13.975 |
| 12:19 ET | 1557 | 13.935 |
| 12:26 ET | 200 | 13.935 |
| 12:28 ET | 249 | 13.919 |
| 12:32 ET | 300 | 13.92 |
| 12:35 ET | 294 | 13.91 |
| 12:37 ET | 112 | 13.935 |
| 12:39 ET | 300 | 13.935 |
| 12:42 ET | 200 | 13.91 |
| 12:46 ET | 100 | 13.89 |
| 12:48 ET | 300 | 13.92 |
| 12:51 ET | 245 | 13.915 |
| 12:55 ET | 100 | 13.915 |
| 12:57 ET | 330 | 13.91 |
| 01:00 ET | 100 | 13.91 |
| 01:02 ET | 1060 | 13.91 |
| 01:04 ET | 319 | 13.91 |
| 01:06 ET | 548 | 13.91 |
| 01:11 ET | 100 | 13.94 |
| 01:22 ET | 100 | 13.925 |
| 01:24 ET | 100 | 13.9338 |
| 01:26 ET | 1307 | 13.905 |
| 01:27 ET | 1600 | 13.92 |
| 01:31 ET | 800 | 13.935 |
| 01:38 ET | 100 | 13.93 |
| 01:42 ET | 300 | 13.95 |
| 01:45 ET | 100 | 13.94 |
| 01:47 ET | 290 | 13.938 |
| 01:49 ET | 930 | 13.94 |
| 01:51 ET | 210 | 13.9241 |
| 01:56 ET | 200 | 13.93 |
| 01:58 ET | 300 | 13.945 |
| 02:00 ET | 100 | 13.96 |
| 02:02 ET | 800 | 13.97 |
| 02:03 ET | 158 | 13.97 |
| 02:05 ET | 100 | 13.95 |
| 02:07 ET | 220 | 13.9617 |
| 02:09 ET | 100 | 13.98 |
| 02:12 ET | 332 | 13.98 |
| 02:14 ET | 400 | 13.955 |
| 02:20 ET | 200 | 13.92 |
| 02:21 ET | 200 | 13.89 |
| 02:23 ET | 200 | 13.88 |
| 02:27 ET | 300 | 13.895 |
| 02:30 ET | 200 | 13.89 |
| 02:32 ET | 400 | 13.87 |
| 02:34 ET | 700 | 13.885 |
| 02:43 ET | 100 | 13.88 |
| 02:45 ET | 700 | 13.89 |
| 02:50 ET | 200 | 13.88 |
| 02:52 ET | 410 | 13.8962 |
| 02:54 ET | 100 | 13.9 |
| 02:56 ET | 1100 | 13.89 |
| 02:59 ET | 600 | 13.88 |
| 03:01 ET | 171 | 13.875 |
| 03:03 ET | 1694 | 13.87 |
| 03:06 ET | 600 | 13.865 |
| 03:10 ET | 100 | 13.84 |
| 03:12 ET | 5725 | 13.88 |
| 03:14 ET | 500 | 13.9 |
| 03:15 ET | 600 | 13.92 |
| 03:17 ET | 1000 | 13.92 |
| 03:19 ET | 100 | 13.92 |
| 03:21 ET | 100 | 13.95 |
| 03:30 ET | 200 | 13.955 |
| 03:32 ET | 400 | 13.96 |
| 03:35 ET | 400 | 13.97 |
| 03:37 ET | 300 | 13.95 |
| 03:39 ET | 600 | 13.95 |
| 03:42 ET | 300 | 13.975 |
| 03:44 ET | 733 | 13.97 |
| 03:46 ET | 1068 | 13.965 |
| 03:48 ET | 300 | 13.965 |
| 03:50 ET | 300 | 13.98 |
| 03:51 ET | 1600 | 13.99 |
| 03:53 ET | 778 | 13.97 |
| 03:55 ET | 2447 | 13.94 |
| 03:57 ET | 3161 | 13.9588 |
| 04:00 ET | 28521 | 13.99 |
Jan 9, 2023
BRIEF-Kiniksa Pharmaceuticals Provides Corporate And Portfolio Update, from 8:29AM ET on Monday Jan 09, 2023 by Thomson Reuters
8:29AM ET on Monday Jan 09, 2023 by Thomson ReutersKiniksa Pharmaceuticals Provides Corporate and Portfolio Update, from 8:00AM ET on Monday Jan 09, 2023 by GlobeNewswire
8:00AM ET on Monday Jan 09, 2023 by GlobeNewswire
Jan 3, 2023
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference, from 4:01PM ET on Tuesday Jan 03, 2023 by GlobeNewswire
4:01PM ET on Tuesday Jan 03, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 972.7M | 7.0x | --- |
Exscientia PLC | 824.5M | -6.6x | --- |
Albireo Pharma Inc | 912.3M | -6.6x | --- |
Rapt Therapeutics Inc | 966.0M | -11.0x | --- |
IGM Biosciences Inc | 962.7M | -4.0x | --- |
Mirum Pharmaceuticals Inc | 880.1M | -20.9x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s portfolio of assets includes ARCALYST (rilonacept), Mavrilimumab, Vixarelimab and KPL-404. The Company's ARCALYST is an interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for treatment of recurrent pericarditis (RP), cryopyrin-associated periodic syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS), and muckle-wells syndrome (MWS) in adults and children. Its Mavrilimumab is a monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα). Its Vixarelimab is a monoclonal antibody inhibitor of signaling through oncostatin M receptor beta (OSMRβ). Its KPL-404 is a monoclonal antibody inhibitor of CD40-CD154 interaction.
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President and Chief Commercial Officer
- Ross Moat
- Senior Vice President and Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $972.7M |
|---|---|
Revenue (TTM) | $177.0M |
Shares Outstanding | 69.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.11 |
EPS | $2.00 |
Book Value | $2.68 |
P/E Ratio | 7.0x |
Price/Sales (TTM) | 5.5 |
Price/Cash Flow (TTM) | 6.7x |
Operating Margin | -18.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
